Zacks Research Brokers Raise Earnings Estimates for TSE:BHC

Bausch Health Companies Inc. (TSE:BHC) – Stock analysts at Zacks Research increased their Q2 2025 earnings per share estimates for Bausch Health Companies in a research note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.52 for the quarter, up from their previous forecast of $1.49. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2025 earnings at $1.67 EPS, Q1 2026 earnings at $1.59 EPS, Q4 2026 earnings at $1.80 EPS, FY2026 earnings at $6.84 EPS and FY2027 earnings at $8.21 EPS.

Bausch Health Companies Price Performance

BHC stock opened at C$9.75 on Thursday. Bausch Health Companies has a 52-week low of C$5.45 and a 52-week high of C$15.43. The stock’s fifty day simple moving average is C$10.42 and its 200-day simple moving average is C$10.57. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of -1,831.94. The stock has a market capitalization of C$2.54 billion, a price-to-earnings ratio of -14.27, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.